JH

Jason Haddock

PYC Therapeutics Limited | Non-Executive Director
Mr Haddock has more than 20 years of financial and operational experience in the biopharmaceutical industry and currently serves as a Board Director of Codiak Biosciences, a biotech company developing precision exosome therapeutics. He served as CFO at Array BioPharma, Inc., where he was instrumental in the execution of an oncology-focused research, development and commercialization strategy that culminated in the successful launch of two new drugs and the company ultimately being acquired by Pfizer. Prior, he worked at Bristol-Myers Squibb in a variety of finance, strategic, commercial and business development capacities, including CFO and COO roles for business units in Asia Pacific, Europe and the United States. Mr. Haddock has also served as CFO for ArcherDX as the company was acquired by Invitae to create a global leader in comprehensive cancer genetics and precision oncology.

Company and Role

Company
Title
Tenure
Since
PYC
PYC Therapeutics Limited
  • Non-Executive Director
3yrs, 2mthMar 2021

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
PYC
PYC Therapeutics Limited
30/06/23N/AN/A1,666,666N/A